Supported by The National Key R and D Program of China,No.2018YFC1314103;The National Natural Science Foundation of China,No.81870563 and No.82270838.
BACKGROUND Insulin antibodies(IAs)affect blood glucose control in patients receiving insulin therapy.AIM To investigate the relationship between different hypoglycemic treatments and IAs in patients with type 2 diabet...
Despite the availability of a variety of insulins,rates of insulinisation and the acceptance of insulin therapy is suboptimal in real-world clinical settings.Patient and physician concerns with hypoglycaemia and weigh...
AIM:To evaluate the safety of four insulin titration algorithms in a homogeneous population of insulin-na ve type 2 diabetic patients.METHODS:We conducted a 24-wk,open,single-center study with 92 insulin-na ve type 2 ...